| 1 |
34312098 | Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently With Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. | 2022 Jan |
2 |
| 2 |
34694666 | Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. | 2021 May |
1 |
| 3 |
31776320 | Capecitabine + Epirubicin + Cyclophosphamide Combination Therapy (CEX Therapy) as Neoadjuvant Chemotherapy for HER-2-Negative Breast Cancer: A Retrospective, Single-Center Study. | 2020 May 15 |
2 |
| 4 |
32211111 | Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. | 2020 |
2 |
| 5 |
32461977 | Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study. | 2020 |
1 |
| 6 |
33299650 | Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer. | 2020 Nov 15 |
1 |
| 7 |
31513391 | HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted Treatment of Ovarian Tumor. | 2019 Oct 14 |
4 |
| 8 |
27530622 | Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. | 2017 May |
2 |
| 9 |
27693116 | Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. | 2017 Feb |
1 |
| 10 |
27721408 | Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. | 2017 Apr |
1 |
| 11 |
26359224 | Advancing pharmacological treatment options for advanced gastric cancer. | 2015 |
1 |
| 12 |
24381054 | Benefit from anthracyclines in relation to biological profiles in early breast cancer. | 2014 Apr |
3 |
| 13 |
25844392 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. | 2014 Apr 9 |
2 |
| 14 |
23450278 | Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. | 2013 Mar |
2 |
| 15 |
23570501 | Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial? | 2013 Apr 9 |
1 |
| 16 |
21920731 | Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. | 2012 Sep |
1 |
| 17 |
22191802 | Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate. | 2012 Feb |
13 |
| 18 |
22240029 | HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. | 2012 Jan 12 |
1 |
| 19 |
26225190 | Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate. | 2012 Nov |
5 |
| 20 |
21788566 | Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | 2011 Sep 1 |
1 |
| 21 |
26229727 | Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. | 2011 Mar |
9 |
| 22 |
19526361 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. | 2010 Feb |
1 |
| 23 |
20332474 | Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer. | 2010 Feb |
1 |
| 24 |
19480561 | Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition. | 2009 Jul |
3 |
| 25 |
18078328 | Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin. | 2008 Feb |
2 |
| 26 |
18270380 | High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin. | 2008 Feb |
2 |
| 27 |
17200359 | Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. | 2007 Jan 1 |
1 |
| 28 |
17324279 | HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. | 2007 Feb 26 |
2 |
| 29 |
17465239 | Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer. | 2007 Mar-Apr |
2 |
| 30 |
17639997 | Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells. | 2007 Aug |
2 |
| 31 |
18086299 | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. | 2007 |
1 |
| 32 |
16781665 | Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. | 2006 Aug 4 |
1 |
| 33 |
15738535 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. | 2005 Jun 1 |
1 |
| 34 |
15970926 | HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. | 2005 Jul 11 |
1 |
| 35 |
16137437 | HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. | 2005 Aug |
1 |
| 36 |
16234514 | retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. | 2005 Oct 20 |
1 |
| 37 |
16234551 | Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer. | 2005 Oct 20 |
1 |
| 38 |
15093573 | Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. | 2004 May |
1 |
| 39 |
15292386 | Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. | 2004 Aug 4 |
1 |
| 40 |
12852361 | [A case of recurrent breast cancer with lung metastasis and overexpression of HER2 that responded to UFT and cyclophosphamide combination therapy after sequential treatments with epirubicin, taxanes, and trastuzumab]. | 2003 Jun |
1 |
| 41 |
14703068 | Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2/neu in patients with breast cancer. | 2003 Dec |
3 |
| 42 |
11583189 | HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. | 2001 Aug |
2 |
| 43 |
11759828 | HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. | 2001 Sep |
1 |
| 44 |
15959941 | Overview of epirubicin-based adjuvant therapy in breast cancer. | 2000 Sep |
1 |
| 45 |
9649144 | Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. | 1998 Jun |
1 |